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In August 2004 pharmacies and drug depots were advised 
that the sole supplier of parenteral phenobarbitone in South 
Africa, essential for the management of status epilepticus in 
children, was stopping production at the end of the same year. 
Alternative protocols for the management of status epilepticus 
resulted in more children requiring intensive care intervention 
(N = 9) at the Red Cross Children’s Hospital, over a 2-month 
period, than had occurred in any 12-month period since 2000 
(2000 N = 3, 2001 N = 1, 2002 N = 1, 2003 N = 2, 2004 N = 7). 
   Other agents that have suffered or are at risk of the same 
fate are sodium nitroprusside, labetalol and esmolol. Sodium 
nitroprusside is used extensively in the peri-operative period 
in cardiac patients requiring after-load reduction. There 
are no other nitrates with equivalent efficacy. Supply was 
stopped in 2005 and only reinstated after the pharmaceutical 
company was contacted directly. Supply of labetalol and 
esmolol was stopped without warning. Without access to 
these products it is necessary to resort to agents that are not 
appropriate for paediatric use. Acetylcysteine (Parvolex), used 
in the management of acetaminophen overdose, also became 
unavailable and the supply was re-established only after direct 
communication with the pharmaceutical company.
   Withdrawal of an essential medicine may be acceptable if 
equivalent agents are available. An equivalent product would 
be one with equal efficacy, side-effects, ease of administration, 
access and cost.
In many centres loss of a single agent is surmountable. 
This is the case in so-called developed countries where lack 
ofaccess to parenteral phenobarbitone is overcome by access 
to intensive care facilities, with adequate nursing and medical 
staff available. However, in the case of children from resource-
poor settings, the impact of removal of a key lifesaving 
medicine can result in increased morbidity and potential 
mortality, as well as greater strain on already challenged health 
systems.
   Health authorities regulate pharmaceutical products coming 
onto the market through strict policing of safety, efficacy 
and quality. However, there is no control over the impact of 
subsequent withdrawal of the product by the Department 
of Health. Pharmaceutical companies are under no legal 
obligation to continue production and marketing of an agent if 
it becomes unprofitable.   
   Given the existing problems of poor access to medication 
and health facilities, in resource-poor settings1 there is 
clearly a need for government legislation on the sustained 
access to ‘essential drugs’. A pharmaceutical company that 
has registered an essential medicine with the Medicines 
Control Council should be compelled to justify its removal 
by establishing either that there is a generic equivalent, an 
effective alternative or an alternative supplier.  
   The World Health Organization (WHO) has established 
an Essential Drugs List (EDL).2 However, these agents 
are not orientated towards child health.3 It has remained 
the responsibility of clinicians to draw attention to these 
‘vulnerable’ medicines nearing extinction.4 These medicines 
are evident both from those products with paediatric relevance 
listed in the WHO EDL,2 as well as the South African EDL 
specifically assessing child health needs.5 Treatment guidelines 
are published and any medicine subsequently withdrawn 
should be managed as an emergency as impact on child 
health will be unavoidable. In the WHO and Integrated 
Management of Childhood Illness (IMCI) guidelines parenteral 
phenobarbitone is first line in the management of neonatal 
seizures and second line for infantile and childhood seizures. 
   The authors motivate that the Department of Health puts in 
place legislation to control the unethical practice of withdrawal 
of essential medicines from paediatric practice.
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